Evidence map›Paper›PMID 40159580›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902).

Ryo Tanaka, Shunji Endo, Toshifumi Yamaguchi, Hiromichi Miyagaki, Junji Kawada, Takeshi Omori, Naoki Takahashi, Toru Masuzawa, Haruna Furukawa, Yuya Sato and 9 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  2. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ryo TanakaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Shunji EndoDepartment of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.
Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, , Takatsuki City, Osaka, Japan. yamagu.toshifumi@gmail.com.ORCID 0000-0003-1399-1918
Hiromichi MiyagakiDepartment of Surgery, Osaka Rosai Hospital, Sakai, Japan.
Junji KawadaDepartment of Surgery, Yao Municipal Hospital, Yao, Japan.
Takeshi OmoriDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Naoki TakahashiDepartment of Gastroenterology, Saitama Prefectural Cancer Center, Saitama, Japan.
Toru MasuzawaDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Haruna FurukawaDepartment of Gastroenterological Surgery, Rinku General Medical Center, Izumisano, Japan.
Yuya SatoDepartment of Gastrointestinal Surgery, Institute of Science Tokyo Hospital, Tokyo, Japan.
Atsushi TakenoDepartment of Surgery, NHO Osaka National Hospital, Osaka, Japan.
Naoki ShinnoDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Ryohei KawabataDepartment of Surgery, Osaka Rosai Hospital, Sakai, Japan.
Shinsuke KatsuyamaDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Shigeyoshi HigashiDepartment of Gastroenterological Surgery, Rinku General Medical Center, Izumisano, Japan.
Yukinori KurokawaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Toshimasa TsujinakaIzumi City General Hospital, Izumi, Japan.
Toshio ShimokawaClinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
Taroh SatohFrontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge type 3 (≥ 8 cm) and type 4 gastric cancers (GCs) have poor prognoses and necessitate multidisciplinary treatment. A multi-institutional phase II study (OGSG1902) was conducted to assess the efficacy and safety of neoadjuvant chemotherapy (NAC) with docetaxel, oxaliplatin, and S-1 (DOS) in these patients.

methodsPatients with large type 3 or type 4 GC without distant metastasis, except for positive peritoneal cytology (CY), were enrolled. Patients received three courses of neoadjuvant DOS therapy (docetaxel 40 mg/m

resultsFrom October 2019 to February 2022, 48 patients were enrolled. NAC was completed in 91.7% of patients. The R0 resection rate was 89.6%. The pathological response rate (Grade 1b-3) was 66.7%. Among patients with measurable lesions, the response rate was 50.0%. The CY-negative conversion rate was 80.0%, and the protocol completion rate was 45.8%. Grade 3 or 4 adverse events during NAC, including neutropenia and appetite loss, occurred in 37.5% of patients. Major postoperative complications (Clavien-Dindo Grade IIIa or higher) were observed in 2.1% of patients.

conclusionsNAC with DOS for large type 3 or type 4 GC followed by gastrectomy demonstrated promising efficacy, high pathological response rates, and an acceptable toxicity profile. Further evaluation of long-term survival outcomes is ongoing.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyStomach NeoplasmsAdultAgedDocetaxelDrug CombinationsFemaleGastrectomyHumansMaleMiddle AgedOxaliplatinOxonic AcidSurvival RateTegafurDocetaxelDrug CombinationsOxaliplatinOxonic AcidS 1 (combination)TegafurAdenocarcinomaNeoadjuvant therapyOxaliplatinScirrhousStomach neoplasms

Identifiers

PMID40159580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.